| 1 |
34996736 | Disentangling the signaling pathways of mTOR complexes, mTORC1 and mTORC2, as a therapeutic target in glioblastoma. | 2022 Jan |
1 |
| 2 |
35586047 | SIK2 Improving Mitochondrial Autophagy Restriction Induced by Cerebral Ischemia-Reperfusion in Rats. | 2022 |
1 |
| 3 |
35613602 | Spatiotemporal feedforward between PKM2 tetramers and mTORC1 prompts mTORC1 activation. | 2022 Jun 13 |
1 |
| 4 |
33219129 | ABHD5 suppresses cancer cell anabolism through lipolysis-dependent activation of the AMPK/mTORC1 pathway. | 2021 Jan-Jun |
1 |
| 5 |
33723393 | Autophagy mediated lipid catabolism facilitates glioma progression to overcome bioenergetic crisis. | 2021 May |
1 |
| 6 |
34376668 | Two parallel pathways connect glutamine metabolism and mTORC1 activity to regulate glutamoptosis. | 2021 Aug 10 |
1 |
| 7 |
34445471 | Evaluation of the Binding Kinetics of RHEB with mTORC1 by In-Cell and In Vitro Assays. | 2021 Aug 16 |
1 |
| 8 |
34523696 | Targeting the mTOR pathway using novel ATP‑competitive inhibitors, Torin1, Torin2 and XL388, in the treatment of glioblastoma. | 2021 Oct |
1 |
| 9 |
34674743 | AZD2014, a dual mTOR inhibitor, attenuates cardiac hypertrophy in vitro and in vivo. | 2021 Oct 21 |
1 |
| 10 |
34927743 | Bone marrow microenvironment drives AML cell OXPHOS addiction and AMPK inhibition to resist chemotherapy. | 2021 Dec 20 |
1 |
| 11 |
31744878 | HSF1-Mediated Control of Cellular Energy Metabolism and mTORC1 Activation Drive Acute T-Cell Lymphoblastic Leukemia Progression. | 2020 Mar |
2 |
| 12 |
32111721 | Correction: An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. | 2020 Feb 28 |
1 |
| 13 |
32323755 | AMPK activation protects astrocytes from hypoxia‑induced cell death. | 2020 May |
1 |
| 14 |
32347294 | Small molecule H89 renders the phosphorylation of S6K1 and AKT resistant to mTOR inhibitors. | 2020 May 29 |
1 |
| 15 |
32351714 | How does mTOR sense glucose starvation? AMPK is the usual suspect. | 2020 |
1 |
| 16 |
32726607 | SGLT2 Inhibition Mediates Protection from Diabetic Kidney Disease by Promoting Ketone Body-Induced mTORC1 Inhibition. | 2020 Sep 1 |
1 |
| 17 |
32848049 | The anti-tubercular activity of simvastatin is mediated by cholesterol-driven autophagy via the AMPK-mTORC1-TFEB axis. | 2020 Dec |
1 |
| 18 |
32883024 | Targeting Oxidative Phosphorylation Reverses Drug Resistance in Cancer Cells by Blocking Autophagy Recycling. | 2020 Sep 1 |
2 |
| 19 |
32956634 | Tacrolimus, a rapamycin target protein inhibitor, exerts anti-cystic echinococcosis effects both in vitro and in vivo. | 2020 Dec |
1 |
| 20 |
33088808 | Neutral Sphingomyelinase-2 (NSM 2) Controls T Cell Metabolic Homeostasis and Reprogramming During Activation. | 2020 |
1 |
| 21 |
30670706 | Mechanistic Target of Rapamycin Complex 1 Promotes the Expression of Genes Encoding Electron Transport Chain Proteins and Stimulates Oxidative Phosphorylation in Primary Human Trophoblast Cells by Regulating Mitochondrial Biogenesis. | 2019 Jan 22 |
2 |
| 22 |
31010692 | Diverse signaling mechanisms of mTOR complexes: mTORC1 and mTORC2 in forming a formidable relationship. | 2019 May |
3 |
| 23 |
31263101 | An ErbB2/c-Src axis links bioenergetics with PRC2 translation to drive epigenetic reprogramming and mammary tumorigenesis. | 2019 Jul 1 |
1 |
| 24 |
31510109 | Second Generation mTOR Inhibitors as a Double-Edged Sword in Malignant Glioma Treatment. | 2019 Sep 10 |
1 |
| 25 |
31921637 | mTORC1 as a Regulator of Mitochondrial Functions and a Therapeutic Target in Cancer. | 2019 |
2 |
| 26 |
29080681 | Uncoupling of ER/Mitochondrial Oxidative Stress in mTORC1 Hyperactivation-Associated Skin Hypopigmentation. | 2018 Mar |
1 |
| 27 |
29195143 | Metabolite identification and pharmacokinetic profiling of PP242, an ATP-competitive inhibitor of mTOR using ultra high-performance liquid chromatography and mass spectrometry. | 2018 Jan 1 |
1 |
| 28 |
29369529 | Diabetes and branched-chain amino acids: What is the link? | 2018 May |
1 |
| 29 |
29571732 | Induction of MEK/ERK activity by AZD8055 confers acquired resistance in neuroblastoma. | 2018 May 15 |
1 |
| 30 |
29692710 | PP242 Counteracts Glioblastoma Cell Proliferation, Migration, Invasiveness and Stemness Properties by Inhibiting mTORC2/AKT. | 2018 |
1 |
| 31 |
29897151 | Quinoline-Glycomimetic Conjugates Reducing Lipogenesis and Lipid Accumulation in Hepatocytes. | 2018 Jun 13 |
2 |
| 32 |
29899840 | CD44 positive and sorafenib insensitive hepatocellular carcinomas respond to the ATP-competitive mTOR inhibitor INK128. | 2018 May 25 |
1 |
| 33 |
30150001 | Metformin as an Anticancer Agent. | 2018 Oct |
1 |
| 34 |
28189457 | Discrete signaling mechanisms of mTORC1 and mTORC2: Connected yet apart in cellular and molecular aspects. | 2017 May |
2 |
| 35 |
28544747 | K-Ras mutation and amplification status is predictive of resistance and high basal pAKT is predictive of sensitivity to everolimus in biliary tract cancer cell lines. | 2017 Sep |
1 |
| 36 |
28707282 | A system to identify inhibitors of mTOR signaling using high-resolution growth analysis in Saccharomyces cerevisiae. | 2017 Aug |
1 |
| 37 |
28885497 | Influence of the Novel ATP-Competitive Dual mTORC1/2 Inhibitor AZD2014 on Immune Cell Populations and Heart Allograft Rejection. | 2017 Dec |
1 |
| 38 |
29245898 | A novel small-molecule arylsulfonamide causes energetic stress and suppresses breast and lung tumor growth and metastasis. | 2017 Nov 21 |
1 |
| 39 |
25867072 | mTOR inhibitors induce apoptosis in colon cancer cells via CHOP-dependent DR5 induction on 4E-BP1 dephosphorylation. | 2016 Jan 14 |
1 |
| 40 |
26563881 | Targeted Inhibition of Rictor/mTORC2 in Cancer Treatment: A New Era after Rapamycin. | 2016 |
2 |
| 41 |
26719046 | ATP-site binding inhibitor effectively targets mTORC1 and mTORC2 complexes in glioblastoma. | 2016 Mar |
2 |
| 42 |
27052953 | mTORC1-Dependent Metabolic Reprogramming Underlies Escape from Glycolysis Addiction in Cancer Cells. | 2016 Apr 11 |
1 |
| 43 |
27338360 | Role of mTOR Inhibitors in Kidney Disease. | 2016 Jun 21 |
1 |
| 44 |
27519418 | Therapeutic Strategy for Targeting Aggressive Malignant Gliomas by Disrupting Their Energy Balance. | 2016 Oct 7 |
2 |
| 45 |
25519700 | MLN0128, an ATP-competitive mTOR kinase inhibitor with potent in vitro and in vivo antitumor activity, as potential therapy for bone and soft-tissue sarcoma. | 2015 Feb |
1 |
| 46 |
25628925 | Dramatic antitumor effects of the dual mTORC1 and mTORC2 inhibitor AZD2014 in hepatocellular carcinoma. | 2015 |
1 |
| 47 |
25692620 | The preclinical evaluation of the dual mTORC1/2 inhibitor INK-128 as a potential anti-colorectal cancer agent. | 2015 |
1 |
| 48 |
26059436 | AMP-activated protein kinase is dispensable for maintaining ATP levels and for survival following inhibition of glycolysis, but promotes tumour engraftment of Ras-transformed fibroblasts. | 2015 May 20 |
2 |
| 49 |
26119735 | mTORC1-Induced HK1-Dependent Glycolysis Regulates NLRP3 Inflammasome Activation. | 2015 Jul 7 |
1 |
| 50 |
26148118 | Potentiation of Growth Inhibitory Responses of the mTOR Inhibitor Everolimus by Dual mTORC1/2 Inhibitors in Cultured Breast Cancer Cell Lines. | 2015 |
1 |